Summary
Updated Aug 30, 2026
Ali J. Satvat is Director of BridgeBio Pharma, Inc. (BBIO). 3 SEC Form 4 filings on record going back to 2024, most recently on 24 June 2026.
Recent Transactions
5Every recent SEC Form 4 transaction Ali J. Satvat has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Ali J. Satvat files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Neil Kumar - $53.07M of BBIO open-market activity in the last 12 months
- Jennifer E. Cook - $21.92M of BBIO open-market activity in the last 12 months
- Frank McCormick - $17.25M of BBIO open-market activity in the last 12 months
- Andrew Lo - $6.32M of BBIO open-market activity in the last 12 months
- Andrea Ellis - $5.65M of BBIO open-market activity in the last 12 months
- Hannah Valantine - $4.37M of BBIO open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Ali J. Satvat?
Ali J. Satvat is a corporate insider, tracked as Director of BridgeBio Pharma, Inc. (BBIO). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Ali J. Satvat submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Ali J. Satvat's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Ali J. Satvat and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
